

Measure Information	2024 Performance Period
Title	Chlamydia Screening in Women
CMS eCQM ID	CMS153v12
CBE ID	Not Applicable
MIPS Quality ID	310
Measure Steward	National Committee for Quality Assurance
Description	Percentage of women 16-24 years of age who were identified as sexually active at any time during the measurement period and who had at least one test for chlamydia during the measurement period
Measure Scoring	Proportion measure
Measure Type	Process measure
Stratification	Report a total score, and each of the following strata:Stratum 1: Patients age 16-20 by the end of the measurement periodStratum 2: Patients age 21-24 by the end of the measurement period
Risk Adjustment	None
Rationale	Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in roughly 1.7 million cases (Centers for Disease Control and Prevention, 2019). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (U.S. Preventive Services Task Force, 2014; Centers for Disease Control and Prevention, 2019).Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (Centers for Disease Control and Prevention, 2019).
Clinical Recommendation Statement	U.S. Preventive Services Task Force (2021) recommends screening for chlamydia in all sexually active women aged 24 years or younger and in women 25 years or older who are at increased risk for infection (B recommendation)
Improvement Notation	Higher score indicates better quality
Definition	None
Guidance	Codes to identify sexually active women include codes for: pregnancy, sexually transmitted infections, contraceptives or contraceptive devices, and infertility treatments.The denominator exclusion does not apply to patients who qualify for the initial population (IP) based on services other than the pregnancy test alone. These other services include services for sexually transmitted infections, contraceptives or contraceptive devices and infertility treatments. For example, a patient who has both a pregnancy test and a chlamydia diagnosis, either of which would qualify them for the IP, would not

Measure Information	2024 Performance Period
	be eligible for this denominator exclusion. This eCQM is a patient-based measure. This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.
Initial Population	Women 16 to 24 years of age by the end of the measurement period who are sexually active and who had a visit in the measurement period
Denominator	Equals Initial Population
Denominator Exclusions	Women who are only eligible for the initial population due to a pregnancy test during the measurement period, and who had an order for an x-ray or for a specified medication on the date of the pregnancy test or the six days after the pregnancy test. Exclude patients who are in hospice care for any part of the measurement period.
Numerator	Women with at least one chlamydia test during the measurement period
Numerator Exclusions	Not Applicable
Denominator Exceptions	None
Telehealth Eligible	Yes